Text Correction
There was an oversight in the original publication [1]. A correction has been made to the Conflicts of Interest statement: The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing P.R. as an inventor. This IP has been licenced to OncoGenex Technologies, a Vancouver-based biotechnology company. P.R. is a co-founder of SilonTx (https://silontx.com), a biotech company started in April 2024, focusing on precision medicine and nucleic acid therapeutics.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Bourefis, A.; Berredjem, H.; Djeffal, O.; Le, T.K.; Giusiano, S.; Rocchi, P. HSP27/Menin Expression as New Prognostic Serum Biomarkers of Prostate Cancer Aggressiveness Independent of PSA. Cancers 2022, 14, 4773. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.